Shuzhen Xiao

Dr. Shuzhen Xiao


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2019 in Antibiotics
Verified
Journal Article
Open access
PDF file
TLTingting Li
Tingting Li
JFJie Feng
Jie Feng
SXShuzhen Xiao
Shuzhen Xiao
WSWanliang Shi
Wanliang Shi
DSDavid Sullivan
David Sullivan
YZYing Zhang
Ying Zhang
Bartonella henselae can cause various infections in humans, ranging from benign and self-limiting diseases to severe and life-threatening diseases as well as persistent infections that are difficult to treat. To develop more effective treatments for persistent Bartonella infections, in this study, we performed a high-throughput screen of an FDA-approved drug library against stationary phase B. henselae using the SYBR Green I/propidium iodide (PI) viability assay. We identified 110 drug candidates that had better activity against stationary phase B. henselae than ciprofloxacin, and among the top 52 drug candidates tested, 41 drugs were confirmed by microscopy to have higher activity than the current frontline antibiotic erythromycin. The identified top drug candidates include pyrvinium pamoate, daptomycin, methylene blue, azole drugs (clotrimazole, miconazole, sulconazole, econazole, oxiconazole, butoconazole, bifonazole), aminoglycosides (gentamicin and streptomycin, amikacin, kanamycin), amifostine (Ethyol), antiviral Lopinavir/ritonavir, colistin, nitroxoline, nitrofurantoin, verteporfin, pentamidine, berberine, aprepitant, olsalazine, clinafloxacin, and clofoctol. Pyrvinium pamoate, daptomycin, methylene blue, clotrimazole, and gentamicin and streptomycin at their respective maximum drug concentration in serum (Cmax) had the capacity to completely eradicate stationary phase B. henselae after 3-day drug exposure in subculture studies. While the currently used drugs for treating bartonellosis, including rifampin, erythromycin, azithromycin, doxycycline, and ciprofloxacin, had very low minimal inhibitory concentration (MIC) against growing B. henselae, they had relatively poor activity against stationary phase B. henselae, except aminoglycosides. The identified FDA-approved agents with activity against stationary phase B. henselae should facilitate development of more effective treatments for persistent Bartonella infections.

22 May 2025 in PLOS ONE
Verified
Journal Article
Open access
HCHongwen Cao
Hongwen Cao
SZSiqi Zhou
Siqi Zhou
XWXuefeng Wang
Xuefeng Wang
SXShuzhen Xiao
Shuzhen Xiao
SZShengyuan Zhao
Shengyuan Zhao
Background: Multidrug-resistant Klebsiella pneumoniae (MDRKP) and carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infections (BSIs) account for significant mortality and healthcare costs. Objectives: To investigate risk factors for MDRKP and CRKP BSIs Methods: A retrospective analysis of inpatients with Klebsiella pneumoniae bloodstream infections (KP BSIs) was conducted in a tertiary care hospital in Shanghai from 01/01/2018–31/12/2022. Temporal distribution of mortality and department distribution of KP BSIs were assessed. A generalized linear model was used to determine risk factors for MDRKP and CRKP BSIs. Results: A total of 379 inpatients with KP BSIs were included. The proportion of death for KP BSIs, MDRKP BSIs and CRKP BSIs gradually decreased since 2020. Majority of both MDRKP and CRKP BSIs patients were from Intensive Care Unit (ICU), burn unit, hematology and pancreatic surgery. Genitourinary disorders, invasive ventilator, history of antibiotic use, and carbapenem use were independently associated with MDRKP BSIs. Respiratory disease, gastric tubes, carbapenem use and its quantity were independently associated with CRKP BSIs. Conclusions: ICU, burn unit, hematology and pancreatic surgery are common departments for MDRKP and CRKP BSIs. Genitourinary disorders, respiratory disorders, invasive ventilator, gastric tubes and antibiotic use (carbapenems in particular) within 90 days prior to onset of BSIs are independently associated with MDRKP and CRKP BSIs.